Cytotoxicity, Immunologic
"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".
This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in Harvard Catalyst Profiles by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 18 | 20 |
| 1995 | 12 | 11 | 23 |
| 1996 | 14 | 16 | 30 |
| 1997 | 12 | 19 | 31 |
| 1998 | 13 | 16 | 29 |
| 1999 | 14 | 23 | 37 |
| 2000 | 12 | 28 | 40 |
| 2001 | 6 | 18 | 24 |
| 2002 | 4 | 18 | 22 |
| 2003 | 4 | 16 | 20 |
| 2004 | 7 | 13 | 20 |
| 2005 | 2 | 10 | 12 |
| 2006 | 3 | 9 | 12 |
| 2007 | 3 | 7 | 10 |
| 2008 | 7 | 9 | 16 |
| 2009 | 3 | 8 | 11 |
| 2010 | 4 | 11 | 15 |
| 2011 | 5 | 12 | 17 |
| 2012 | 1 | 11 | 12 |
| 2013 | 5 | 16 | 21 |
| 2014 | 8 | 9 | 17 |
| 2015 | 3 | 8 | 11 |
| 2016 | 2 | 13 | 15 |
| 2017 | 8 | 16 | 24 |
| 2018 | 4 | 17 | 21 |
| 2019 | 4 | 17 | 21 |
| 2020 | 5 | 11 | 16 |
| 2021 | 2 | 8 | 10 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 2 | 3 |
| 2024 | 0 | 2 | 2 |
Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.
-
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer? Oncoimmunology. 2024; 13(1):2324493.
-
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024 Jan 02; 15(1):89.
-
Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers. Immunity. 2023 Dec 12; 56(12):2816-2835.e13.
-
Co-expression of HLA-E and HLA-G on genetically modified porcine endothelial cells attenuates human NK cell-mediated degranulation. Front Immunol. 2023; 14:1217809.
-
Profiling of Natural Killer Interactions With Cancer Cells Using Mass Cytometry. Lab Invest. 2023 08; 103(8):100174.
-
Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth In Vivo. ACS Nano. 2022 08 23; 16(8):12695-12710.
-
All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity. Front Immunol. 2022; 13:896228.
-
CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity. Nat Commun. 2022 04 07; 13(1):1899.
-
Extracellular matrix proteins regulate NK cell function in peripheral tissues. Sci Adv. 2022 03 18; 8(11):eabk3327.
-
Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use. Cytotherapy. 2022 03; 24(3):334-343.